Can molecular patterns help to classify overlapping entities in myeloid neoplasms?

被引:1
作者
Hoermann, Gregor [1 ]
Khoury, Joseph D. [2 ]
机构
[1] MLL Munich Leukemia Lab, Munich, Germany
[2] Univ Nebraska Med Ctr, Nebraska Med Ctr 985900, Dept Pathol Microbiol & Immunol, Omaha, NE 68198 USA
关键词
chronic myelomonocytic leukaemia; disease classification; genetics; molecular patterns; myelodysplastic neoplasms; myeloid neoplasms; myeloproliferative neoplasms; systemic mastocytosis; EARLY PRIMARY MYELOFIBROSIS; TYROSINE KINASE JAK2; CLONAL HEMATOPOIESIS; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; RING SIDEROBLASTS; MYELODYSPLASTIC SYNDROMES; INTEROBSERVER VARIANCE; REFRACTORY-ANEMIA; SETBP1; MUTATIONS;
D O I
10.1111/his.15339
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Myeloid neoplasms include myeloproliferative and myelodysplastic neoplasms and acute myeloid leukaemia. Historically, these diseases have been diagnosed based on clinicopathological features with sometimes arbitrary thresholds that have persisted even as molecular features were gradually incorporated into their classification. As such, although current diagnostic approaches can classify the majority of myeloid neoplasms accurately using a combination of molecular and clinicopathological features, some areas of overlap persist and occasionally pose diagnostic challenges. These include overlap across BCR::ABL1-negative myeloproliferative neoplasms; between clonal cytopenia of undetermined significance and myelodysplastic neoplasms; myelodysplastic/myeloproliferative neoplasms; and, detection of KIT mutations in myeloid neoplasms other than mastocytosis, raising the prospect of systemic mastocytosis. Molecular testing has become state of the art in the diagnostic work-up of myeloid neoplasms, and molecular patterns can inherently help to classify overlapping entities if considered within a framework of haematological presentations. For future development, molecular testing will likely include whole genome and transcriptome sequencing, and primarily molecular classifications of myeloid neoplasms have already been suggested. As such, genetically defined groups should still constitute the basis for our understanding of disease development from early onset to progression, while clinicopathological features could then be used to describe the stage of the disease rather than the specific type of myeloid neoplasm. Molecular testing has become state of the art in the diagnostic work-up of myeloid neoplasms and molecular features have been incorporated into their classification, together with clinicopathological features. Molecular patterns can inherently help to classify overlapping entities if considered within a framework of haematological presentations. image
引用
收藏
页码:146 / 157
页数:12
相关论文
共 41 条
  • [31] Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34)
    Visconte, V.
    Shetty, S.
    Przychodzen, B.
    Hirsch, C.
    Bodo, J.
    Maciejewski, J. P.
    Hsi, E. D.
    Rogers, H. J.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 (04) : 409 - 417
  • [32] Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm-a comparison of 756 cases
    Baer, Constance
    Pohlkamp, Christian
    Haferlach, Claudia
    Kern, Wolfgang
    Haferlach, Torsten
    LEUKEMIA, 2018, 32 (10) : 2295 - 2298
  • [33] Clinical Aspects and Significance of β-Chemokines, γ-Chemokines, and δ-Chemokines in Molecular Cancer Processes in Acute Myeloid Leukemia (AML) and Myelodysplastic Neoplasms (MDS)
    Korbecki, Jan
    Bosiacki, Mateusz
    Stasiak, Piotr
    Snarski, Emilian
    Brodowska, Agnieszka
    Chlubek, Dariusz
    Baranowska-Bosiacka, Irena
    CANCERS, 2024, 16 (19)
  • [34] Designing Myeloid Gene Panels Evaluation of the Association for Molecular Pathology-Recommended Core 34-Gene Panel for Next-Generation Sequencing in Chronic Myeloid Neoplasms
    Zhao, Fang
    Bosler, David S.
    Cook, James R.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2022, 146 (08) : 1004 - 1011
  • [35] Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes
    Badar, Talha
    Szabo, Aniko
    Sallman, David
    Komrojki, Rami
    Lancet, Jefferey
    Padron, Eric
    Song, Jinming
    Hussaini, Mohammad Omar
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1418 - 1427
  • [36] Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features
    Wechalekar, Mihir D.
    Zhao, Lin-Pierre
    Kutyna, Monika M.
    Hong, Lih En
    Li, Joule
    Hung, Kevin
    Scott, Hamish S.
    Brown, Anna
    Hahn, Christopher C.
    Kassahn, Karin
    Ladon, Dariusz
    Yeung, David T.
    Thomas, Daniel
    Patnaik, Mrinal
    Proudman, Susanna
    Ades, Lionel
    Shah, Mithun V.
    Kok, Chung H.
    Hiwase, Devendra K.
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [37] Arginase-1+bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver
    Bonometti, Arturo
    Borsani, Oscar
    Rumi, Elisa
    Ferretti, Virginia Valeria
    Dioli, Claudia
    Lucato, Elena
    Paulli, Marco
    Boveri, Emanuela
    CANCER MEDICINE, 2023, 12 (07): : 7815 - 7822
  • [38] The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers
    Meggendorfer, M.
    Haferlach, C.
    Zenger, M.
    Macijewski, K.
    Kern, W.
    Haferlach, T.
    LEUKEMIA, 2016, 30 (07) : 1624 - 1627
  • [39] Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia
    Dovey, Oliver M.
    Cooper, Jonathan L.
    Mupo, Annalisa
    Grove, Carolyn S.
    Lynn, Claire
    Conte, Nathalie
    Andrews, Robert M.
    Pacharne, Suruchi
    Tzelepis, Konstantinos
    Vijayabaskar, M. S.
    Green, Paul
    Rad, Roland
    Arends, Mark
    Wright, Penny
    Yusa, Kosuke
    Bradley, Allan
    Varela, Ignacio
    Vassiliou, George S.
    BLOOD, 2017, 130 (17) : 1911 - 1922
  • [40] Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2
    Baer, Constance
    Muehlbacher, Verena
    Kern, Wolfgang
    Haferlach, Claudia
    Haferlach, Torsten
    HAEMATOLOGICA, 2018, 103 (08) : E348 - E350